Health Canada Approves ibrutinib for Mantle Cell Lymphoma NewsResearch Health Canada Approves ibrutinib for Mantle Cell Lymphoma
Specific subtype of diffuse large B-cell lymphoma more likely to respond to ibrutinib NewsResearch Specific subtype of diffuse large B-cell lymphoma more likely to respond to ibrutinib
Aggressive lymphoma linked to disruption in cell energy production NewsResearch Aggressive lymphoma linked to disruption in cell energy production
Understanding risks and managing expectations around relapse Research Understanding risks and managing expectations around relapse
European Hematology Association Congress 2015 NewsResearch European Hematology Association Congress 2015
Y-ibritumomab tiuxetan and high-dose BEAM chemotherapy conditioning followed by autologous stem cell transplantation shows encouraging response and survival rates in refractory diffuse large B-cell lymphoma patients Research Y-ibritumomab tiuxetan and high-dose BEAM chemotherapy conditioning followed by autologous stem cell transplantation shows encouraging response and survival rates in refractory diffuse large B-cell lymphoma patients
Potential Role of Lymphocyte Development Gene Variants in Non-Hodgkin Lymphoma Risk Research Potential Role of Lymphocyte Development Gene Variants in Non-Hodgkin Lymphoma Risk
Rituximab helps overcome adverse effects of diabetes mellitus for patients with diffuse large B-cell lymphoma. Research Rituximab helps overcome adverse effects of diabetes mellitus for patients with diffuse large B-cell lymphoma.
LR11: a novel biomarker identified in follicular lymphoma Research LR11: a novel biomarker identified in follicular lymphoma